IL309097A - Methods for treating seizures caused by a nerve agent - Google Patents

Methods for treating seizures caused by a nerve agent

Info

Publication number
IL309097A
IL309097A IL309097A IL30909723A IL309097A IL 309097 A IL309097 A IL 309097A IL 309097 A IL309097 A IL 309097A IL 30909723 A IL30909723 A IL 30909723A IL 309097 A IL309097 A IL 309097A
Authority
IL
Israel
Prior art keywords
methods
induced seizures
nerve agent
treating nerve
treating
Prior art date
Application number
IL309097A
Other languages
English (en)
Hebrew (he)
Inventor
Christopher Francis Toombs
Original Assignee
Proniras Corp
Christopher Francis Toombs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proniras Corp, Christopher Francis Toombs filed Critical Proniras Corp
Publication of IL309097A publication Critical patent/IL309097A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL309097A 2021-06-09 2022-06-09 Methods for treating seizures caused by a nerve agent IL309097A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163208885P 2021-06-09 2021-06-09
PCT/US2022/032783 WO2022261287A1 (en) 2021-06-09 2022-06-09 Methods of treating nerve agent-induced seizures

Publications (1)

Publication Number Publication Date
IL309097A true IL309097A (en) 2024-02-01

Family

ID=84425551

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309097A IL309097A (en) 2021-06-09 2022-06-09 Methods for treating seizures caused by a nerve agent

Country Status (10)

Country Link
US (1) US20240277696A1 (enExample)
EP (1) EP4352047A4 (enExample)
JP (1) JP2024521430A (enExample)
KR (1) KR20240022544A (enExample)
CN (1) CN117836284A (enExample)
AU (1) AU2022291138A1 (enExample)
CA (1) CA3222575A1 (enExample)
IL (1) IL309097A (enExample)
MX (1) MX2023014418A (enExample)
WO (1) WO2022261287A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511741B1 (en) * 2002-04-26 2012-12-26 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
US11045462B2 (en) * 2016-06-14 2021-06-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods for treating neurological conditions and exposure to nerve agents
WO2018169798A1 (en) * 2017-03-11 2018-09-20 The Regents Of The University Of California Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers

Also Published As

Publication number Publication date
WO2022261287A1 (en) 2022-12-15
JP2024521430A (ja) 2024-05-31
KR20240022544A (ko) 2024-02-20
MX2023014418A (es) 2024-02-13
CN117836284A (zh) 2024-04-05
EP4352047A4 (en) 2025-04-16
EP4352047A1 (en) 2024-04-17
US20240277696A1 (en) 2024-08-22
AU2022291138A1 (en) 2023-12-07
CA3222575A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
IL299206A (en) Methods for treating cancer using heteroaryl-biphenyl amide derivatives
EP4111202A4 (en) CANCER TREATMENT METHODS
IL315503A (en) Treatment methods
ZA202400405B (en) Methods of treating neurological diseases
IL320711A (en) Treatment methods
IL289811A (en) A method for treating cancer
IL309097A (en) Methods for treating seizures caused by a nerve agent
SG11202107017TA (en) Methods of treating cancer
GB202201824D0 (en) Methods of treatment
IL321201A (en) Methods for treating neurological disorders
IL288003A (en) Cancer treatment methods using chk1 inhibitors
GB202107994D0 (en) Treatment of cancer
IL312155A (en) A method for treating cancer
EP4351727A4 (en) METHOD OF TREATMENT OF DRUG-RESISTANT EPILEPSY
IL272390A (en) Cancer treatment methods
GB202201819D0 (en) Methods of treatment
GB202201825D0 (en) Methods of treatment
IL307291A (en) Methods for treating inflammation
HUE066685T2 (hu) Multifokális rák kezelési eljárásai
IL312332A (en) Cancer treatment methods
HK40112465A (en) Methods of treating brain cancer
IL308511A (en) A method for treating essential tremor
IL315569A (en) Cancer treatment methods
IL326537A (en) A method for treating seizures
HK40109326A (en) Methods of treating cancer